Mirikizumab (Omvoh) is effective in inducing a clinical response in adults with moderate-to-severe ulcerative colitis and ...

A variant of the Aeromonas bacterium promoted colon inflammation in mice and was detected in stools and colon tissue from ...

The discovery that a toxin made by bacteria found in dirty water might help trigger ulcerative colitis could lead to new ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...

A toxin-secreting gut bacterium may fuel ulcerative colitis by killing protective immune cells that maintain intestinal ...

Johnson & Johnson Pvt. Ltd. (JnJ) has been asked to justify key aspects of its proposed Phase III clinical trial protocol for ...

Week held in Berlin, Germany, an informative session explored emerging approaches for the management of ulcerative colitis (UC), ranging from surgical interventions to updated treatment guidelines and ...

AnaptysBio (ANAB) just revealed that its Phase 2 trial for rosnilimab in moderate-to-severe ulcerative colitis is being discontinued because the treatment did not outperform placebo in reaching ...

(MENAFN- EIN Presswire) EINPresswire/ -- According to DataM Intelligence, the ulcerative colitis treatment market size reached US$ 7.60 billion in 2023, increased to US$ 7.98 billion in 2024, and is ...

A toxin-secreting gut bacterium may fuel ulcerative colitis by killing protective immune cells that maintain intestinal homeostasis, according to a ...

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...